|
Radiant Biotherapeutics, a biotechnology company committed to advancing a breakthrough antibody approach, the Multabody, for a broad range of therapeutic areas, including cancer and infectious diseases, announced new data at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting demonstrating its lead oncology candidate, RBT-101, exhibited robust, durable and complete tumour regression while avoiding liver toxicity, in a MC38 colorectal mouse tumour model.
Radiant’s proprietary Multabody technology uniquely harnesses natural mechanisms to effectively engage multiple disease targets with unmatched strength, precise tunability, and exceptional breadth. 4-1BB is a clinically validated immune checkpoint target that elicits potent anti-tumour immunity and enhanced T cell responses but has eluded safe and effective therapeutic targeting by traditional 4-1BB agonists due to systemic and Fc-mediated liver toxicity. Radiant has leveraged its Multabody platform to develop RBT-101, a multivalent 4-1BB agonist that does not rely on traditional antibody methods to enhance potency, binding strength or durability.
Key Highlights from SITC 2025 Poster Presentation:
- RBT-101 achieved sustained complete tumour regression in MC38 colorectal mouse tumour model
- RBT-101 demonstrated long-lived anti-tumour immunological memory; no detectable tumour growth was observed in mice that were re-challenged with MC38 tumour cells after previous successful treatment
- RBT-101 demonstrated no signs of liver toxicity, in contrast to benchmark 4-1BB agonist urelumab
“Our data to be presented at SITC demonstrates that RBT-101 achieves what first-generation 4-1BB agonists could not – delivering robust anti-tumour activity without liver toxicity,” said Jo Hulme, Ph.D., CSO of Radiant. “This validates our Multabody platform’s potential to address a broad range of therapeutic targets while avoiding the inherent limitations of conventional antibody-based approaches, as RBT-101 drove potent, tunable and safe agonism of 4-1BB that more closely mimicked natural ligand biology. We look forward to the continued development of Multabodies as promising therapeutics in oncology and other disease areas.”
The poster, titled “Multabodies: A next-generation approach for cancer immunotherapy and 4-1BB agonist therapy,” will be presented onsite on Friday, November 7, 2025, and will also be available on the SITC virtual meeting platform beginning November 7 at 9 a.m. ET.
Radiant Biotherapeutics is a biotechnology company advancing breakthrough Multabody therapeutics that deliver unmatched strength, tunability, and breadth in a single molecule. The company’s proprietary platform leverages apoferritin scaffolding and sophisticated protein engineering to create antibodies with unprecedented therapeutic potential across a broad range of disease areas, including cancer and infectious diseases.
|